Cantor Fitzgerald Starts Cerus (CERS) at Buy; Potential Game-Changer in Blood

Cantor Fitzgerald initiates coverage on Cerus (NASDAQ: CERS) with a Buy. PT $5.50.

Analyst, Jeremy Feffer, said, "With ~100 million blood transfusions performed globally each year, we believe that Cerus’ pathogen inactivation technology will eventually become standard of care in this $6 billion global market. European blood centers have begun to adopt Cerus' Intercept system as current blood testing methods are inadequate to detect 100% of possible infections. With numerous geographic expansion and pipeline opportunities on the horizon, the stock is extremely attractive at current levels, in our view."

For an analyst ratings summary and ratings history on Cerus click here. For more ratings news on Cerus click here.

Shares of Cerus closed at $3.56 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight
• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
• TD Cowen Assumes Agios Pharma (AGIO) at Buy